Fig. 3
From: Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer
The HRD status and clinical outcomes in validation group of EOC. The median intervals of PARPi in positive HRD EOC patients were longer than negative HRD patients. The median PFS of positive HRD EOC patients were longer than negative HRD patients. Note: The blue row indicated the interval of the patient taking PARPi. The orange row indicated progression free survival of the patient. The dark blue cross indicated the patient stopped taking PARPi. The light blue arrow indicated the patient keep PARPi. The red cross indicated cancer recurrence or persistent disease. The light red arrow indicated no evidence of cancer recurrence